Dihexa, also referenced as PNB-0408, is a synthetic oligopeptide structurally related to angiotensin IV. It has been described as a hepatocyte growth factor / c-Met system modulator, though that description carries an important caveat that shapes how we read the current evidence. Two foundational mechanistic papers, one from 2012 and a seminal 2014 study, were reviewed by a University of Washington group and retracted for data falsification and inappropriate imaging. The retractions do not erase the cognitive and synaptic findings seen with dihexa. They reopen the question of which pathway actually drives those effects.

This lesson covers the proposed mechanisms, the preclinical evidence, and where the molecular story remains unsettled.

Mechanism and the open pathway question

As an angiotensin IV analog, dihexa may act through inhibition of the IRAP enzyme that degrades peptides such as somatostatin, vasopressin, the enkephalins, and oxytocin. That mechanism is tied to altered microglial activation, a more anti-inflammatory environment in the brain, and conditions that support synaptic plasticity and neurogenesis. The alternative proposed mechanism, allosteric potentiation of hepatocyte growth factor signaling through c-Met, is the pathway most affected by the retractions. Dr. Seeds suggests the angiotensin IV route deserves closer attention, while noting that c-Met involvement has not been excluded and may be modulatory rather than tumor-promoting.

Preclinical evidence

Across multiple rodent models, dihexa reversed cognitive deficits in scopolamine-induced amnesia and improved learning and memory in APP/PS1 transgenic Alzheimer’s mice. Reported effects include increased dendritic spine density, higher synapsin protein, reduced apoptosis, and a shift toward an anti-inflammatory cytokine profile. A PI3K inhibitor reversed dihexa’s effects, pointing to PI3K/AKT signaling as central to its cytoprotective action. Oral activity, blood-brain-barrier penetration, and metabolic stability were confirmed in animal work. Beyond cognition, dihexa protected zebrafish hair cells from aminoglycoside ototoxicity and, combined with mesenchymal stem cells, supported peripheral nerve repair.

Safety and regulatory status

Dihexa is not FDA approved for any indication. No human clinical trials, human pharmacokinetic data, or long-term carcinogenicity studies exist. Because the hepatocyte growth factor / c-Met pathway is a validated oncologic driver, with FDA-approved cancer drugs designed to inhibit it, chronic c-Met enhancement raises a theoretical tumorigenesis concern that has not been resolved.

Key clinical points

• Dihexa is an oral, blood-brain-barrier-permeable angiotensin IV analog studied for cognitive and synaptic effects.
• Two foundational c-Met mechanistic papers (2012, 2014) were retracted; the behavioral, synaptogenic, and PI3K/AKT findings remain unretracted.
• Evidence is preclinical only, with no human trials, no human pharmacokinetics, and no long-term carcinogenicity data.
• The proposed c-Met pathway overlaps with a known oncologic mechanism, which is why the molecular target needs further validation.
• Reported clinical use is anecdotal, with full patient disclosure of its non-approved, research-compound status.